Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Donanemab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Alzheimer Disease & Dementia) and 15,000 total planned enrollment. 5 Phase 3 Donanemab trials and 3 Phase 2, 1 Phase 4 are listed. 4 Donanemab clinical trials are actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT06566170 (Feb 2033).
Where to Participate: All Donanemab Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting Donanemabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
LY3002813A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
PSEN1A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
13 Donanemab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 5 are marked completed.
Are Donanemab clinical trials recruiting in 2026?
Yes — 1 Donanemab trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
What conditions is Donanemab being studied for?
Donanemab is being studied for Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Neurodegenerative Diseases and 16 more. The trials are grouped by indication on this page.
What phase is Donanemab in?
Donanemab clinical trials span 1 Phase 4, 5 Phase 3, 3 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Donanemab clinical trials?
The lead sponsor across the most Donanemab trials is Eli Lilly and Company, with 3 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Donanemabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.